Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Jazz Pharmaceuticals (Nasdaq: JAZZ) were playing a beautiful tune today and climbed 14% in intraday trading.

So what: Revenues jumped 60% to $64.6 million, and earnings per share were $0.71 in the second quarter. That's fine and dandy, but the full-year forecast caught investors' eyes when Jazz said it was expecting between $247 million and $260 million in revenue and earnings per share between $2.68 and $2.79.

Now what: Analysts were expecting 2011 to be at the lower end of what Jazz gave for guidance, so it wasn't like these were blowout numbers, but a better-than-expected guidance is a good step. On the balance sheet, Jazz prepaid $33 million of long-term debt on July 1, strengthening an already strong balance sheet. The company has now beat estimates for four straight quarters, one of this Fool's favorite signs of a stock moving higher.

Interested in more info on Jazz Pharmaceuticals? Add it to your watchlist.